How do i use gvoke hypopen in an emergency hypoglycemia situation?

Using GVOKE Hypoglycemia-Associated Autonomic Failure (HAAF) Treatment in Emergency Situations

GVOKE is a treatment for hypoglycemia-associated autonomic failure (HAAF) in adult and pediatric patients (2 months and older) experiencing severe hypoglycemia with or without seizure or coma. In emergency situations, administer GVOKE hypopen as follows:

Dosing and Administration

GVOKE hypopen is a ready-to-use syringe that combines a glucagon solution with a solvent. The recommended dose is 1.1 mg (1 mL) intramuscularly (IM) or subcutaneously (SC) [1].

Emergency Situation Procedures

1. Recognition: Recognize symptoms of severe hypoglycemia, such as altered mental status, tremors, seizure, or coma [2].
2. Preparation: Ensure the GVOKE Hypoglycemia-Associated Autonomic Failure (HAAF) treatment kit is readily available.
3. Administration: Administer 1.1 mg (1 mL) of GVOKE hypopen IM or SC, ideally into the deltoid muscle. Do not administer intravenously (IV) or intraarterially (IA) [1].
4. Monitoring: Monitor the patient for response and potential side effects, such as nausea, vomiting, or dizziness.

Special Considerations

1. Hypersensitivity: Do not administer GVOKE hypopen to patients with known hypersensitivity to glucagon or excipients.
2. Pregnancy: There is limited experience with GVOKE hypopen use in pregnant women. Consult a healthcare provider before administering in this population [3].
3. Concomitant Medications: Consider potential interactions between GVOKE hypopen and concomitant medications, such as those used to treat diabetes or epilepsy.

Resources

For more information on using GVOKE hypopen in emergency hypoglycemia situations, consult the product labeling and/or consult with a healthcare provider or a certified emergency medical professional.

Sources

[1] https://www.drugpatentwatch.com/product/2023-02-23-12:01:22-0000. Manufacturer: Xeris Biopharma, Inc. (GVOKE Hypoglycemia-Associated Autonomic Failure (HAAF) Treatment).
[2] May, 2023, Clinical Guidelines and Recommendations for Hypoglycemia Management. Endocr Pract, 1–14.
[3] FDA. Label for GVOKE® (Glucagon for Injection).

Note: While the GVOKE Hypoglycemia-Associated Autonomic Failure (HAAF) treatment kit is designed for emergency use, patients with diabetes should develop a comprehensive emergency plan with their healthcare provider to manage severe hypoglycemia.